Country for PR: United States
Contributor: PR Newswire New York
Friday, November 22 2019 - 00:00
Seed Health Announces Research Partnership with Atmo Biosciences to Evaluate Impact of Probiotics With First Ingestible Gas Sensor Technology
LOS ANGELES, Nov. 21, 2019 /PRNewswire-AsiaNet/ --

-- First tech-enabled clinical trial will use new biomarkers to measure effect
   of Seed's Daily Synbiotic on gut microbiome after antibiotic use

Seed Health ( 
), a microbial sciences company, today announced a research partnership with 
digital health company, Atmo Biosciences ( 
), to use the world's first ingestible gas-sensing capsule technology in 
clinical trials to profile key gases produced within the gut in real-time. The 
first trial will evaluate the impact of probiotics on the gut microbiome after 
antibiotic use. 

Photo -  

"Despite over a decade of human microbiome research, we are still limited by 
the technologies available to measure and understand real-time activity in the 
human gut," said Raja Dhir, Seed Health co-founder and co-CEO. "We are inspired 
by this collaboration with Atmo Biosciences as we pioneer new biomarkers and 
methods to measure the impact of specific probiotics, while deepening our 
functional understanding of the gut microbiome. The ability to monitor this 
environment has tremendous implications for the future of the field." 

The lower gut is challenging to reach physically, making it difficult to study 
clinically. To date, gut microbiome research-and studies on the efficacy of 
interventions like probiotics-has relied largely on stool analysis, which is 
more reflective of the gut lumen microbiome, specifically in the colon. Other 
than an invasive tube insertion, the only way to test for key gases is by 
breath measurements, which are often inaccurate as gas concentrations in the 
gut are 5,000-10,000 times higher than the breath. Other diagnostic methods 
such as aspiration, biopsy, endoscopy, motility pills, and imaging pills are 
also often highly invasive, costly, or have other clinical limitations. 

To better understand the gut microbiome, scientists have sought new 
methodologies and biomarkers to safely and more precisely measure 
gastrointestinal activity. 

The Atmo Gas Capsule, published in Nature Electronics ( 
), is the first ingestible sensor technology to track location-specific gases 
through the human gastrointestinal tract. The 28mm capsule uses sensors to 
measure key gases present, including hydrogen and oxygen, and is up to 3,000 
times more accurate than breath tests. Development is underway to include 
additional biomarkers such as methane, hydrogen sulfide, and short-chain fatty 
acids-an additional cluster of biomarkers key to understanding gut microbiota 
function. The data is transmitted every 6 minutes for up to 5 days to a small 
receiver, which then transmits the data via Bluetooth to a mobile phone for 
ease of monitoring by users, researchers, and clinicians. Collectively, these 
new biomarkers empower researchers to gain objective, real-time insight into 
patient gut health for diagnosis, treatment, and how interventions like 
antibiotics, probiotics, and food may impact gut function.

Seed(R) ( 
), the consumer health division of Seed Health, will use Atmo's Gas Capsule in 
a series of upcoming clinical studies on their flagship probiotic, the Daily 
Synbiotic ( 
). The first clinical study, authorized by Health Canada NHPD, will build on 
previous metagenomic studies and measure both the effects of antibiotics on the 
entire GI tract, and how the use of specific strains of probiotic bacteria may 
impart functional benefits to the GI system after antibiotic therapy. 

"While antibiotics are a key frontline tool to treat and eliminate infections, 
they're also known to negatively impact the diversity and function of the gut 
microbiome as reflected in the variety of side effects they cause," said Dr. 
Gregor Reid, Distinguished Professor at Western University and Lawson Institute 
Chair of Human Microbiology and Probiotics, and Seed's Chief Scientist. "As a 
research and clinical tool, this device will contribute greatly to learning how 
interventions, including probiotics, alter the gut microbiome's activity and 
metabolic readouts."

Patients enrolled in this first study will swallow an Atmo Gas Capsule for 
continuous monitoring, detection, and measurement of key gases and volatile 
compounds. After the capsule has passed through the gut, it then exits intact 
within the stool, and is discarded. Additionally, the study will collect urine, 
vaginal swabs, and fecal and blood samples at multiple unique time points. 
Recruitment for this study is scheduled to begin in December with the trial 
commencing in early 2020.

"Working with Seed Health, we can now expand the potential of our technology to 
understand and measure the real-time impact of interventions like probiotics 
under different conditions," said Atmo Biosciences CEO, Mal Hebblewhite. "Our 
technology unlocks new datasets and novel biomarkers that could not only impact 
the millions who currently suffer from GI disorders and food intolerances, but 
also offer an entirely new dimension of research to evaluate interventions and 
preventive measures, which could impact millions more." 

About Seed Health
Seed Health is a microbial sciences company pioneering applications of bacteria 
to impact human and environmental health. In collaboration with leading 
academic partners, Seed Health's foundry model accelerates breakthrough science 
to develop live biotherapeutics and consumer innovations. The portfolio targets 
some of the most pressing, pervasive conditions for which microbes can become 
or replace the primary standard of care. Seed Health's first foundry company is 
LUCA Biologics ( 
), a biotechnology company developing a new class of living medicines targeting 
the vaginal microbiome to impact reproductive and urogenital health.

About Seed(R)
Seed develops broad spectrum and targeted consumer probiotics from 
strain-specific research validated in human clinical trials. Seed's platform is 
built on a global strain bank, and includes technology-enabled gastrointestinal 
simulation models, human cell line and antibiotic resistance testing, 
untargeted metabolomics and whole genome sequencing. Seed's life science 
approach brings much-needed precision, efficacy and education to the global 
probiotics market. Seed is the consumer division of Seed Health.

About Atmo Biosciences

Atmo Biosciences is a digital health business underpinned by a world-first 
ingestible gas-sensing capsule technology developed at RMIT University. When 
swallowed, the Atmo Gas Capsule can profile the gas biomarkers within the gut 
in real-time, leading to better diagnosis and assessment of treatments for 
gastrointestinal disorders, and the monitoring of microbiome function, leading 
to improved gut health and wellness.

Jonathon O'Leary

SOURCE: Seed Health